India’s biotechnology sector has expanded steadily over the past decade, supported by government initiatives, academic research, and startup incubation programs. While established companies often dominate public attention, a smaller group of recently founded startups is beginning to shape the next phase of innovation.
India is home to a growing number of biotech startups in India in 2026, along with a growing number of Indian life sciences companies, reflecting broader biotech industry India trends and increasing focus on biotech innovation in India. These biotech companies in India are contributing to developments in healthcare and industrial applications.
India’s bioeconomy has grown significantly, with estimates placing it at over $130 billion and a rapidly increasing number of biotech startups contributing across healthcare, agriculture, and industrial biotechnology.⁶ These newer companies, many founded between 2023 and 2024, operate in areas such as genomics, diagnostics, therapeutics, and industrial biotechnology. Unlike technology startups, biotech ventures often remain less visible in their early years due to longer research and validation timelines.
Cities like Bengaluru and Hyderabad continue to act as major hubs for biotech innovation in India, supported by biotech incubation programs, early-stage biotech funding in India, and a growing network of BIRAC-supported startups.
Many biotech startups in India are supported by government-backed programs such as the Biotechnology Industry Research Assistance Council (BIRAC), along with incubators and academic institutions that help translate laboratory research into commercial ventures and support clinical translation.⁷
This article highlights five recently founded new biotech startups in India that are working on scientifically relevant problems and have verifiable initial development presence.
Founded: 2023
BacAlt Biosciences focuses on developing bio-based materials using microbial fermentation processes. The company works on producing alternatives to conventional materials through biological systems. It is currently in an initial development phase, with its work centered on platform and process development.
The company converts agro-industrial and post-harvest waste into biopolymers using energy-efficient and non-sterile fermentation processes.¹
Its platform is intended to produce biopolymers that can be used as ingredients across multiple sectors, including home care, personal care, pharmaceuticals, and nutraceuticals. These materials may function as thickeners, stabilizers, excipients, and binding agents depending on application.
Industrial biotechnology, particularly fermentation-based production, has gained importance due to its potential to reduce dependence on petrochemical-derived materials. Microbial systems can be engineered to produce polymers and other biomolecules in controlled environments.
These biopolymers are being explored as alternatives to synthetic ingredients used in sectors such as home care, personal care, agriculture, and pharmaceuticals, with a focus on reducing microplastic pollution.¹
The company also reports that its non-sterile fermentation approach reduces energy requirements compared to traditional sterile processes and supports scalability by improving process efficiency.
This approach aligns with broader efforts in the biotech industry India trends to build a bioeconomy that emphasizes sustainability and resource efficiency. Early-stage funding reported for the company suggests early investor interest.¹
Founded: 2023
Precision Health Innovations Pvt Ltd is developing a DNA-based platform that integrates genomics with artificial intelligence for disease prediction, diagnosis, and treatment planning. The company appears to be in an early research stage.
Its approach aligns with broader precision health frameworks that combine environmental, community, and biological data to improve disease surveillance and early warning systems, particularly in vulnerable populations.
Genomic medicine is increasingly used in oncology and rare diseases, where identifying specific mutations can guide targeted therapies. The integration of AI supports analysis of large datasets generated from sequencing technologies.
Precision health as a field emphasizes predictive, preventive, and personalized care by integrating genetic, environmental, and lifestyle data.
The company’s work reflects broader developments among biotech research startups and drug discovery startups in India, where treatment decisions are informed by genetic information rather than population averages.²
Founded: 2024
Trucan Diagnostics Pvt Ltd develops diagnostic solutions focused on improving accessibility and speed of testing. The company operates within the point-of-care diagnostics segment and is likely in a prototype or early deployment stage.
The company focuses on providing rapid diagnostic tools that can support decentralized healthcare settings and reduce dependence on centralized laboratory infrastructure.
According to publicly available information from its platform, Trucan Sentinel, the company is engaged in research and development activities related to diagnostic technologies.
Point-of-care testing allows results to be obtained near the patient rather than in centralized laboratories. This can reduce turnaround time and support faster clinical decision-making.
Such systems are particularly relevant in settings with limited laboratory infrastructure. Advances in biosensors and miniaturized diagnostic devices have made portable testing more feasible in recent years. Developments in diagnostics also contribute to the growth of healthcare startups in India and a broader One Health perspective by improving disease detection across human and animal health systems.³
Founded: 2024
Utopia Therapeutics is a biotechnology company focused on vaccine development and translational research. Its work follows a pipeline-based approach typical of vaccine-focused companies, including discovery and early translational stages.
The company’s research includes identifying antigens, developing delivery systems, and progressing vaccine candidates through early development phases.
Vaccine research involves multiple stages including discovery, preclinical evaluation, and clinical trials. As a company working in early translational phases, its activities align with established vaccine development pathways.
The COVID-19 pandemic increased attention toward vaccine platforms and highlighted the importance of domestic research capabilities. Companies in this space typically operate through phased pipelines that include discovery, preclinical testing, and clinical trials.⁴
Founded: 2024
Transcript Life Sciences focuses on developing therapeutics that target ribosomal mechanisms involved in protein synthesis. The company appears to be in an early research stage.
The company is working on therapeutic platforms that involve modulation of protein synthesis pathways through ribosomal targets.
The ribosome plays a central role in translating genetic information into proteins. Targeting ribosomal pathways has been explored in areas such as antimicrobial therapy and cancer treatment.
Advances in molecular biology and structural biology have improved understanding of ribosomal function, allowing researchers to explore more specific interventions. This area remains complex but holds potential for therapeutic research within life sciences startups in India.⁵
A review of these companies highlights several trends in India’s newer biotech ecosystem:
Growth of genomics and precision medicine
Expansion of point-of-care diagnostics
Interest in vaccine and therapeutic development
Use of biological systems for industrial applications
Increasing integration of artificial intelligence with biological data
These trends reflect global shifts in biotechnology while also addressing local healthcare and infrastructure needs.
Despite their potential, biotech companies face several challenges:
Long research and development timelines
Regulatory requirements for clinical validation
High capital requirements
Limited early-stage visibility
A major challenge in biotechnology is the gap between laboratory research and clinical application, where promising findings often require extensive validation before reaching patients.
The five startups highlighted in this article represent a segment of India’s biotechnology ecosystem working across industrial biotechnology, genomics, diagnostics, and therapeutics.
While these companies are in early stages, their focus areas align with scientific and healthcare priorities. Their progress will depend on continued research, regulatory progress, and successful translation from laboratory findings to real-world applications.
These startups highlight their potential role in improving healthcare accessibility and scalability in India.
These biotech startups in India also reflect a broader shift toward biotech research startups and drug discovery startups in India. This progress is supported by increasing biotech funding in India and stronger startup ecosystems, along with a continued focus on clinical translation.
As part of the broader landscape of biotech startups in India 2026, these companies illustrate how innovation, infrastructure, and funding are contributing to the development of the biotech industry in India.
“BacAlt Biosciences Raises Funding for Bio-Based Materials.” Entrackr.
https://entrackr.com/snippets/bacalt-biosciences-raises-2-mn-in-pre-seed-round-led-by-avaana-capital-10229378
“Genomics and Medicine.” National Human Genome Research Institute.
https://www.genome.gov/health/Genomics-and-Medicine
“Point-of-Care Diagnostics: Technologies and Applications.” NCBI.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354544/
“Vaccine Development Process.” National Institute of Allergy and Infectious Diseases (NIAID).
https://www.niaid.nih.gov/research/vaccine-development
“Ribosome-Targeting Antibiotics.” Nature Reviews Microbiology.
https://www.nature.com/articles/s41579-020-00426-5
“India Bioeconomy Report.” Department of Biotechnology (DBT), Government of India.
https://dbtindia.gov.in/sites/default/files/India%20Bioeconomy%20Report%202023.pdf
“Biotechnology Industry Research Assistance Council (BIRAC).” Government of India.
https://birac.nic.in/